Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Clinical Trials
149
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (121 trials with phase data)• Click on a phase to view related trials
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT07117487
- Locations
- 🇺🇸
Velocity Clinical Research, Denver, Denver, Colorado, United States
🇺🇸Indago Research & Health Center, Inc., Hialeah, Florida, United States
🇺🇸Velocity Clinical Research, Savannah, Savannah, Georgia, United States
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Drug: mRNA-2808
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 166
- Registration Number
- NCT07116616
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
- Conditions
- COVID-19
- Interventions
- Biological: mRNA-1283 Variant-containing Formulation
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT07089706
- Locations
- 🇺🇸
DelRicht Research-Atlanta, Atlanta, Georgia, United States
🇺🇸DelRicht Research-Baton Rouge, Baton Rouge, Louisiana, United States
🇺🇸DelRicht Research-New Orleans, New Orleans, Louisiana, United States
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880536
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880549
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 22
- Next
News
FDA Plans to Present Data Linking COVID-19 Vaccines to 25 Pediatric Deaths at CDC Advisory Meeting
The FDA plans to present data at next week's CDC Advisory Committee on Immunization Practices meeting claiming to link COVID-19 vaccines to 25 deaths in children, based on analysis of VAERS database reports.
Quotient Sciences and CPI Form Joint Venture to Accelerate RNA Drug Development with Integrated Manufacturing Platform
Quotient Sciences and CPI have signed a memorandum of understanding to form a joint venture combining Quotient's Translational Pharmaceutics® platform with CPI's RNA manufacturing expertise.
IQVIA and Flagship Pioneering Form Strategic Alliance to Accelerate Biotech Innovation Through AI-Powered Drug Development
IQVIA and Flagship Pioneering announced a strategic collaboration in August 2025 to accelerate breakthrough life sciences companies using AI-powered analytics and clinical trial expertise.
Circurna Partners with GATC Health to Accelerate Circular RNA Therapeutics Using AI Platform
Circurna and GATC Health announced a strategic partnership to apply advanced AI technology for optimizing circular RNA therapeutics development.
COVID-19 Vaccine Stocks Plummet on Reports of Potential Market Withdrawal
Vaccine manufacturers experienced significant stock declines following reports that the US government may remove mRNA COVID-19 vaccines from the market within months.
Axelyf Closes $2.6M Seed Round to Advance Superior RNA-LNP Gene Editing Technology
Axelyf Inc. secured $2.6 million in seed funding led by Brunnur Ventures to develop its proprietary AXL lipid nanoparticle technology for RNA therapeutics.
Influenza Pipeline Surges with 120+ Therapies as Moderna, AstraZeneca Lead Innovation Wave
The global influenza pipeline has expanded to include 120+ companies developing 120+ treatment therapies, with breakthrough innovations spanning vaccines, antibodies, and combination therapies.
IO Biotech's Melanoma Vaccine Narrowly Misses Primary Endpoint in Phase 3 Trial Despite Promising Subgroup Results
IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056.
FDA Considers Revoking Pfizer COVID-19 Vaccine Authorization for Children Under 5
The FDA is considering not renewing Pfizer's emergency use authorization for its COVID-19 vaccine in children aged 6 months to 4 years for the upcoming respiratory season.
Genvira and Labskin Secure £1.2 Million UK-Canada Grant for Melanoma Immunotherapy Development
Genvira Biosciences and Labskin Limited have received £1.2 million ($2.0 million) in funding through the Canada-UK Biomanufacturing of Biologics and Advanced Therapies program to develop novel melanoma immunotherapies.